Home Health Index March Update
The home health and post-acute care indices had a better-than-usual month on the public markets in March, the first time in a while since the majority of the public companies were all up in one month.
There are several factors that were contributing to the uncertainty – money is still sitting on the sidelines because of interest rates. Home care providers were in limbo regarding the Medicaid Access rule, which unfortunately was just finalized with the 80-20 provision in tact, having what industry experts believe will be catastrophic consequences to providers, especially smaller ones.
But for March, providers should be happy to have a month where the trajectory was pointed upward for basically the whole group.
“There will undoubtedly be shake-ups across home-based care, now that the Medicaid Access rule has been finalized,” says Ben Bogan, Partner and Managing Director at Stoneridge Partners. “Some of that M&A hesitation and turbulent stock movement had already occurred, but it seems certain that there will be more turbulence to come with the 80-20 provision making its way to the final rule.”
Certainly, some home-and community-based services (HCBS) providers – namely Addus HomeCare Corp. (Nasdaq: ADUS) and Aveanna Healthcare Holdings (Nasdaq: AVAH) – were hoping the Medicaid Access rule would be dismantled altogether, but that hope is now gone.
In a speech in early April, President Joe Biden himself seemed to foreshadow recent events while touting the looming rule.
“In the coming weeks, we plan to release new rules to strengthen staffing standards in nursing homes, to get home care workers a bigger share of Medicaid payments,” Biden said at Union Station in Washington, D.C., on April 9.
The home health index was up 1.7% in March, while the post-acute care index was up 6.77%. Comparatively, the S&P was up 4.38% month over month.
Home Health Index
The home health index numbers deserve some context.
Enhabit Inc. (Nasdaq: EHAB) was up over 22% on the month.
Amedisys, one of the only providers that ticked downward in the month, was down by just under 1%. But it holds greater weight than Enhabit.
Amedisys was likely down due to all the antitrust noise around UnitedHealth Group (NYSE: UNH), which agreed in June of last year to acquire Amedisys.
Though there were reports suggesting the deal would be scrutinized even more heavily in the coming months, it will likely go through, albeit with some caveats.
The probable scenario is Amedisys will be forced to divest some of its assets, particularly the ones that overlap with LHC Group, another home health company that UnitedHealth Group officially acquired early last year.
Enhabit remains in the late innings of its strategic review, and it’s unclear now what will ultimately be the result of that review. The result could be a sale, a merger or neither. Perhaps the company’s leaders will unveil more on a May 9 first-quarter earnings call.
“We are in the later stages of our strategic review, but don’t intend to disclose developments unless and until we determine further disclosure is appropriate or necessary. We will not be commenting beyond that,” Enhabit CEO Barb Jacobsmeyer said on the company’s first-quarter earnings call.
Post-Acute Care Index
In the post-acute care index, BrightSpring rebounded quickly from a rocky start on the public market. The company was up over 17% in March.
Meanwhile, The Pennant Group was up 4.99%; Addus was up 10.67%; and Aveanna was up 4.82%.
The Pennant Group has been one of the top gainers over the last year. Over the past year, the company is up over 50%. It has been one of the only companies that has continued regularly executing M&A deals, along with Addus.
One of the main keys to its success is its independence from the fee-for-service Medicare dollar. While others have been scrambling to adjust to a Medicare Advantage-dominated world, Pennant seems to have a solid plan and has adjusted well.
“Our model enables us to adapt and respond to changing circumstances and market needs on a macro and local level,” Pennant CEO Brent Guerisoli said last year. “It also allows us to be nimble and take advantage of unique opportunities, including payer relationships, preferred provider networks and localized reimbursement programs.”
Quote of the Month
“It is unfortunate that the final rule included a mandatory pass-through requirement. There are so many positive and necessary changes in the regulation, so it is disappointing that this one provision will undermine all the good things about the rule.” – David Totaro, President and Executive Director of Bayada’s Hearts for Home Care and NAHC MAC’s co-chair
Read the Full Article Here: Home Care Industry Slams Finalized 80-20 Rule, Warns Agency Closures are Coming
See It To Believe It!
The Stoneridge Partners Home Health Index (HH Index) is updated monthly and measures the performance of these two publicly traded home health companies, all listed on the NASDAQ:
- Amedisys (AMED)
- Enhabit (EHAB)
Here are the results of the stock prices for the past two years:
Company | 3/31/24 | 1 mos change | YTD change | 3/31/23 | 3/31/22 |
Amedisys | 92.16 | -0.93% | -3.05% | 73.55 | 172.29 |
Enhabit | 11.65 | +22.83% | +12.56% | 13.91 | – |
HH Index* | 51.91 | +1.73% | -1.52% | 43.73 | 170.45 |
S&P | 5329.75 | +4.38% | +11.30% | 4109.31 | 4550.5 |
Enterprise Value (EV)
EV (in M) | 2024 | 2023 | 2022 |
Amedisys | 3370 | 2810 | 6300 |
Enhabit | 1170 | 1290 | – |
HH Index Total | 4540 | 4100 | 12340 |
Enterprise Value (EV), aka Selling Price, as Percent of Revenue
Company | 2024 | 2023 | 2022 |
Amedisys | 151% | 126% | 284% |
Enhabit | 112% | 119% | – |
HH Index Average* | 132% | 123% | 278% |
The Stoneridge Partners Post-Acute Care Index is updated monthly and measures the performance of these seven publicly traded post-acute care companies, all listed on the NASDAQ:
- Aveanna (AVAH)
- Amedisys (AMED)
- Addus (ADUS)
- The Pennant Group, Inc. (PNTG)
- Enhabit (EHAB)
- Brookdale Senior Living Inc. (BKD)
- Brightspring (BTSG)
Here are the results of the Post-Acute stock prices for the past two years:
Company | 3/31/24 | 1 mos change | YTD change | 3/31/23 | 3/31/22 |
---|---|---|---|---|---|
Amedisys | 92.16 | -0.93% | -3.05% | 73.55 | 172.29 |
Addus | 103.34 | +10.67% | +11.30% | 106.76 | 93.29 |
Pennant | 19.63 | +4.99% | +41.02% | 14.28 | 18.63 |
Brookdale | 6.61 | +13.62% | +13.57% | 2.95 | 7.05 |
Enhabit | 11.65 | +22.83% | +12.56% | 13.91 | – |
Brightspring
Aveanna |
10.87
2.49 |
+17.30%
+2.95% |
–
-7.09% |
–
1.04 |
–
– |
Enterprise Value (EV)
EV (in M) | 2024 | 2023 | 2022 |
---|---|---|---|
Amedisys | 3370 | 2810 | 6300 |
Addus | 1790 | 1760 | 1500 |
Pennant | 913 | 727 | 1140 |
Brookdale | 567 | 490 | 603 |
Enhabit | 1170 | 1290 | – |
Brightspring
Aveanna |
5520
1780 |
–
1550 |
–
– |
Enterprise Value (EV), aka Selling Price, as Percent of Revenue
Company | 2024 | 2023 | 2022 |
---|---|---|---|
Amedisys | 151% | 126% | 284% |
Addus | 169% | 185% | 174% |
Pennant | 168% | 154% | 269% |
Brookdale | 189% | 178% | 219% |
Enhabit | 112% | 119% | – |
Brightspring
Aveanna |
63%
94% |
–
89% |
–
– |
This graph displays 24 months of Post-Acute Care Index performance.
The above calculations are based on selling price being defined as Enterprise Value (EV), with data provided by Capital IQ. Enterprise value is defined as market cap plus debt, minority interest and preferred shares, minus total cash and cash equivalents. EBITDA is calculated using methodology which may differ from that used by a company for its reporting. (Home Health Index March 2024 | Stoneridge Partners)
Recent Transactions From Around The Country
- Frontpoint Health has acquired High Plains Senior Care Group.
- Waud Capital has acquired the home care franchise Senior Helpers.
SOLD by Stoneridge!!!
- Stoneridge Partners is proud to announce the successful sale of a Home Care Agency in Maryland.
- Stoneridge Partners is proud to announce the successful sale of a Behavioral Health Facility in Texas.
View Stoneridge closed transactions on our website
Exclusively Listed For Sale By Stoneridge Partners.
Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.
Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.
Therapy provider serving patients of all ages for over 10 years. $3.5M in revenue with solid EBITDA margins. Great year over year revenue growth. Good...
Nurse registry. $7M in revenue. 100% private pay. Primarily non-medical home care. District 9.
Medicare-certified hospice agency. Licensed to serve the entire state of Pennsylvania. No census.
Long-established Medicare/Medicaid home health agency with multiple locations. $7.3M in revenue. Good payor mix. On Homecare Homebase.
Home health agency in 2 states, one a CON. $3M+ in revenue. Good payor mix. 5-star patient survey rating.
Home care agency. $2.5M in revenue. 60% Private Pay/40% VA.
Home care franchisee. Long-established territory. $2M in revenue. Expansive service area with growth potential.
I/DD provider offering SCL & FHP services. $3M in revenue. Recent rate increase. Strong history in their community.
Healthcare staffing agency. $2.6M in revenue. R.N., C.N.A., L.P.N., surgical tech, medical assistant, & clinical therapist staffing services. Long-established staffing agency operating for 45 years...
Behavioral health provider. $5.5M+ revenue with solid EBITDA margins. Leading edge service provider and with proprietary state contracts. Unique combination of service options and contracts...
Medicaid/Medicare home health & home care company. $2.5M in revenue. Well-established. Stable revenue. Profitable year-over-year.
I/DD provider. $2.6M+ in revenue with 19% EBITDA margins. CARF accredited, long history in the community. Mix of county contracts and Medicaid payors. Consistently recognized...
Medicare-certified home health agency. District 7. Census of approximately 30 patients. Accredited.
Designer/Distributor of innovative, therapeutic, health and wellness personal products. $1.5M+ in revenue. Launched in the US and UK, now launching into the EU. Nearly 7,000...
Staffing Agency licensed to provide staffing services in 6 states. $ 2.4M+ in LTM revenue. Significant long-term contracts with providers in the Care-At-Home space, Health...
Homecare agency. $6.5M+ in revenue. Located on Long Island. Blend of Private Duty & Medicaid patients.
Large home care franchisee. $26M+ in revenue. 89% Medicaid. Well-established company operating over 20 years. Phenomenal year-over-year revenue growth.
Maricopa County hospice. 40+ ADC. CHAP accredited. No CAP or regulatory issues.
Growing ABA (Autism) therapy clinic established in 2020. $1.6M in revenue. Market demand heavily outweighs supply in the area for ABA therapy.
Well-established private pay agency in the Denver area. $ 2M in revenue. Profitable. Diverse list of referral sources.
Northeast Oklahoma home health company. $1.7M of revenue and profitable. 95% traditional Medicare. Long history in the area.
Special education and tutorial provider with limited access contracts. $3M in revenue. Strong relationships with county school programs. Long history in the community, close to...
Medicare-certified home health agency. $1.7M in revenue. AHCA accredited. Broward County (Region 10)
Growing Medicare home health and hospice organization. $17M+ in revenue. Over 25 years in business. A well-established leader in the market.
Home Health / West / Popular
Medicare-certified home health agency. Region 7, including sought-after Orange county (Orlando). Minimal census.
Behavioral health services. $25+M in revenue. Residential care facilities, inpatient psych/outpatient mental health support services, and counseling for adults and elderly patients. Platform opportunity with...
Skilled home health agency. Servicing Central Florida for over 20 years. Census approximately 35.
Occupational therapy practice with 2 offices in Southern California. Hand and upper extremity specialists. 20-plus years in the community. Strong referral relationships. Management and staff...
$5M in revenue. Located in Northern/Richmond VA. Health system-owned Medicare home health and hospice. Growing organization.
Medicare-certified home health. Opportunity to establish home health presence in Texas. Minimal census.
Medicare/Medicaid-certified home health agency. $1.4M in revenue. District 9. Profitable. Accredited.
Home care agency. $30M+ in revenue. 95% Medicaid. Platform opportunity.
Home Care / New Mexico / Popular
Hospice. 45+ ADC. Rio Grande Valley. No CAP or regulatory issues.
$40M+ home care agency with 20+% AEBITDA. Primarily private-duty, non-medical (90%). Medicaid waiver programs. 40% family caregivers. Multiple locations.
Home Care / Pennsylvania / Popular
Medicare-certified home health agency. District 3. Approximately $700k in revenue. Accredited.
Home Health / Florida / Popular
Home Health Index March 2024 | Stoneridge Partners
From Ben Bogan, Publisher of “Home Health Index.” Ben can be reached at [email protected] or (239) 561-0826, and toll-free at 800-218-3944. Previous editions of this monthly newsletter can be searched for at the bottom of the home page of the Home Health Index.
Ben Bogan, J.D., Partner and Managing Director at Stoneridge Partners, has been a leading figure in healthcare M&A since 2014, specializing in home health, home care, and hospice transactions. With over 70 successful closed deals, Ben’s experience and expertise have set him apart as a skilled and invaluable intermediary in the industry.
With a law degree from Albany Law School, a BSBA in Economics from the University of Florida, and his background as a former Assistant District Attorney and Assistant District Counsel for the U.S. Army Corps of Engineers, Ben combines his legal background and M&A expertise to deliver exceptional results in every transaction. Available to his clients 24/7, Ben builds strong relationships with his clients and has garnered rave reviews.
For more information, please contact Ben directly at 520-991-4653 or [email protected]. All communications are confidential.